Anti CD19 CAR‑NK cell therapy (Chongqing Precision Biotech)

N/A

Report date: 2025/02/06 10:25:17

Base Information

Drug NameAnti CD19 CAR‑NK cell therapy (Chongqing Precision Biotech)
Drug Alias NameCAR NK-cell therapy (Chongqing Precision Biotech)anti-CD19 CAR NK-cell therapy (Chongqing Precision Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesChongqing Precision Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChongqing Precision Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A